Will Donnellan

2.0k total citations
6 papers, 73 citations indexed

About

Will Donnellan is a scholar working on Oncology, Pathology and Forensic Medicine and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Will Donnellan has authored 6 papers receiving a total of 73 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 2 papers in Pathology and Forensic Medicine and 2 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Will Donnellan's work include CAR-T cell therapy research (3 papers), Lymphoma Diagnosis and Treatment (2 papers) and Acute Lymphoblastic Leukemia research (2 papers). Will Donnellan is often cited by papers focused on CAR-T cell therapy research (3 papers), Lymphoma Diagnosis and Treatment (2 papers) and Acute Lymphoblastic Leukemia research (2 papers). Will Donnellan collaborates with scholars based in United States, Australia and South Korea. Will Donnellan's co-authors include Leon Bernal‐Mizrachi, Rajni Sinha, Mary Jo Lechowicz, David L. Jaye, Uma Borate, Christopher R. Flowers, Pareen J. Shenoy, Vishnu Reddy, James M. Foran and Jeanne Kowalski and has published in prestigious journals such as Blood, Leukemia & lymphoma and HemaSphere.

In The Last Decade

Will Donnellan

6 papers receiving 72 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Will Donnellan United States	4	46	37	19	16	16	6	73
Rathana Kim France	5	18 0.4×	22 0.6×	29 1.5×	8 0.5×	32 2.0×	11	73
G.K. Bascom United States	2	41 0.9×	27 0.7×	9 0.5×	8 0.5×	10 0.6×	2	63
Yuka Iijima‐Yamashita Japan	5	24 0.5×	15 0.4×	23 1.2×	22 1.4×	24 1.5×	10	58
Emily C. Ayers United States	5	33 0.7×	35 0.9×	12 0.6×	11 0.7×	3 0.2×	19	69
Krista M. Isaac United States	6	60 1.3×	32 0.9×	23 1.2×	22 1.4×	7 0.4×	11	105
Danielle Leão Cordeiro de Farias Brazil	6	33 0.7×	35 0.9×	17 0.9×	19 1.2×	4 0.3×	15	93
Dhanalaxmi Shetty India	6	26 0.6×	32 0.9×	66 3.5×	20 1.3×	59 3.7×	9	112
Astrid Pavlovsky Argentina	5	32 0.7×	22 0.6×	8 0.4×	18 1.1×	3 0.2×	21	62
Carlos Litovich United States	6	65 1.4×	80 2.2×	15 0.8×	6 0.4×	5 0.3×	12	99
Jarosław Czyż Poland	6	23 0.5×	23 0.6×	45 2.4×	33 2.1×	12 0.8×	17	85

Countries citing papers authored by Will Donnellan

Since Specialization

Citations

This map shows the geographic impact of Will Donnellan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Will Donnellan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Will Donnellan more than expected).

Fields of papers citing papers by Will Donnellan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Will Donnellan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Will Donnellan. The network helps show where Will Donnellan may publish in the future.

Co-authorship network of co-authors of Will Donnellan

This figure shows the co-authorship network connecting the top 25 collaborators of Will Donnellan. A scholar is included among the top collaborators of Will Donnellan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Will Donnellan. Will Donnellan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Shah, Bijal, Michael R. Bishop, Aaron C. Logan, et al.. (2019). PS945 KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA: END OF PHASE 1 RESULTS OF ZUMA-3. HemaSphere. 3(S1). 426–426. 1 indexed citations

2.

Sallman, David A., Will Donnellan, Adam Asch, et al.. (2019). S878 THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 IS ACTIVE AND WELL TOLERATED ALONE OR IN COMBINATION WITH AZACITIDINE IN AML AND MDS PATIENTS: INITIAL PHASE 1B RESULTS. HemaSphere. 3(S1). 394–394. 9 indexed citations

3.

Cortes, Jörge E., Justin M. Watts, Thomas Prébet, et al.. (2018). FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study. Blood. 132(Supplement 1). 1452–1452. 14 indexed citations

4.

Donnellan, Will, et al.. (2016). Gamma-Delta T Cell Acute Lymphoblastic Leukemia: A Single-Center Experience. 2(1). 26–29. 2 indexed citations

5.

Flowers, Christopher R., Pareen J. Shenoy, Uma Borate, et al.. (2012). Examining racial differences in diffuse large B-cell lymphoma presentation and survival. Leukemia & lymphoma. 54(2). 268–276. 44 indexed citations

6.

Flowers, Christopher R., Loretta J. Nastoupil, Uma Borate, et al.. (2012). Racial Disparities in Cell of Origin Among DLBCL Patients.. Blood. 120(21). 2686–2686. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact